- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07504458
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia (QUATRO-APL)
A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia
This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33000
- Recruiting
- Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Sud, Centre François Magendie
-
Principal Investigator:
- Pierre-Yves Dumas, MD
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
La Tronche, France, 38700
- Recruiting
- CHU Grenoble Alpes - Hôpital Michallon
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Principal Investigator:
- Martin Carre, MD
-
Nancy, France, 54500
- Recruiting
- Centre Hospitalier Régional Universitaire (CHRU) de Nancy - Hôpitaux de Brabois
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Principal Investigator:
- Caroline Bonmati, MD
-
Nice, France, 06202
- Recruiting
- Centre Hospitalier Universitaire (CHU) de Nice - Hôpital de l'Archet 1
-
Principal Investigator:
- Thomas Cluzeau, MD
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Paris, France, 75010
- Recruiting
- Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis
-
Principal Investigator:
- Pierre Fenaux, MD
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Saint-Priest-en-Jarez, France, 42270
- Recruiting
- Centre Hospitalier Universitaire (CHU) de Saint-Étienne - Hôpital Nord
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Principal Investigator:
- Emmanuelle Tavernier-Tardy, MD
-
Strasbourg, France, 67000
- Recruiting
- Hôpitaux Universitaires de Strasbourg
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Principal Investigator:
- Marie-Pierre Ledoux, MD
-
-
-
-
-
Roma, Italy, 00133
- Recruiting
- Hospital Tor Vergata Roma
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Principal Investigator:
- Maria Teresa Voso, MD
-
Vicenza, Italy, 36100
- Recruiting
- Azienda ULSS 8 Berica - Ospedale San Bortolo
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Principal Investigator:
- Maria Cristina Miggiano, MD
-
-
-
-
-
Cluj-Napoca, Romania, 400015
- Recruiting
- Institutul Oncologic "Prof. Dr. Ion Chiricuță"
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Principal Investigator:
- Minhea Zdrenghea, MD
-
-
-
-
-
Badalona, Spain, 08916
- Recruiting
- Institut Català d'Oncologia (ICO) Badalona - Hospital Universitari Germans Trias i Pujol
-
Principal Investigator:
- Susana Vives Polo, MD
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Barcelona, Spain, 08035
- Recruiting
- Hospital Universitari Vall d'Hebron
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Principal Investigator:
- Olga Salamero Garcia, MD
-
Barcelona, Spain, 08041
- Recruiting
- Hospital de la Santa Creu i Sant Pau
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Principal Investigator:
- Ana Garrido Diaz, MD
-
Cáceres, Spain, 10003
- Recruiting
- Hospital Universitario San Pedro de Alcántara
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Principal Investigator:
- Juan Miguel Bergua Burgúes, MD
-
Málaga, Spain, 29010
- Recruiting
- Hospital Regional Universitario de Málaga
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Principal Investigator:
- Alejandro Contento Gonzalo, MD
-
Oviedo, Spain, 33011
- Recruiting
- Hospital Universitario Central de Asturias
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Principal Investigator:
- Maria Teresa Bernal Castillo, MD
-
Valencia, Spain, 46026
- Recruiting
- Hospital Universitario y Politécnico La Fe
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Principal Investigator:
- Pau Montesinos Fernández, MD
-
-
Balearic Islands
-
Palma de Mallorca, Balearic Islands, Spain, 07120
- Recruiting
- Hospital Universitari Son Espases
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Principal Investigator:
- Andres Novo Garcia, MD
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- University of Alabama at Birmingham (UAB)
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Contact:
- Quetzal Therapeutics Investigator
- Email: ClinicalTrials@QuetzalTx.com
-
Principal Investigator:
- Sravanti Rangaraju, MD
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope Comprehensive Cancer Center
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Principal Investigator:
- Vinod Pullarkat, MD
-
Irvine, California, United States, 92612
- Recruiting
- University of California, Irvine
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Principal Investigator:
- Kiran Naqvi, MD
-
Los Angeles, California, United States, 90033
- Recruiting
- USC Norris Comprehensive Cancer Center
-
Principal Investigator:
- Eric Tam, MD
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Orange, California, United States, 92868
- Recruiting
- UCI Health - UCI Medical Center
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Principal Investigator:
- Kiran Naqvi, MD
-
Stanford, California, United States, 94305
- Recruiting
- Stanford University School of Medicine
-
Principal Investigator:
- Tian Yi Zhang, MD
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Recruiting
- Augusta University Medical Center
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Principal Investigator:
- Anand Jillella, MD
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- Recruiting
- University of Kentucky Markey Cancer Center
-
Principal Investigator:
- Ayman Qasrawi, MD
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Contact:
- Quetzal Therapeutics Investigator
- Email: ClinicalTrials@QuetzalTx.com
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Recruiting
- University of Maryland Medical Center
-
Principal Investigator:
- Maria Baer, MD
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Contact:
- Quetzal Therapeutics Investigator
- Email: ClinicalTrials@QuetzalTx.com
-
Baltimore, Maryland, United States, 21231
- Recruiting
- Johns Hopkins Kimmel Cancer Center
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Principal Investigator:
- Gabriel Ghiaur, MD
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- University of Michigan
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Contact:
- Quetzal Therapeutics Investigator
- Email: ClinicalTrials@QuetzalTx.com
-
Principal Investigator:
- Dale L Bixby, MD
-
-
New York
-
Buffalo, New York, United States, 14203
- Recruiting
- Roswell Park Comprehensive Cancer Center
-
Principal Investigator:
- Eunice Wang, MD
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
The Bronx, New York, United States, 10467
- Recruiting
- Montefiore Medical Center
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
Principal Investigator:
- Aditi Shastri, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- Recruiting
- University of North Carolina at Chapel Hill
-
Principal Investigator:
- Joshua Zeidner, MD
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Recruiting
- The Ohio State University Wexner Medical Center
-
Principal Investigator:
- Uma Borate, MD
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Recruiting
- Sarah Cannon Research Institute at TriStar Centennial Medical Center
-
Principal Investigator:
- Steven Strickland, MD
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas MD Anderson Cancer Center
-
Principal Investigator:
- Farhad Ravandi, MD
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- Recruiting
- University of Virginia Health
-
Principal Investigator:
- Daniel Reed, MD
-
Contact:
- Quetzal Therapeutics Investigator
- Phone Number: +13126800501
- Email: ClinicalTrials@QuetzalTx.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Informed Consent
- Participants must be between 18 and under 71 years of age
- Participants must have a confirmed diagnosis of APL proven by standard genetic testing (t(15;17) or PML-RARA)
- Participants must be classified as low- or intermediate-risk APL
- Participants must be willing and able to comply with the scheduled study visits, treatment plans, laboratory tests, contraception guidance, and other procedures
Exclusion Criteria
- Participants who have significant heart rhythm problems including long QT syndrome, serious arrhythmias, very slow heart rate, or prolonged QTc on ECG
- Participants who have central nervous system leukemia
- Participants having serious ongoing medical conditions or infections including uncontrolled infections, severe organ disease, or conditions that make study participation unsafe
- Participants who are pregnant, breastfeeding, or unwilling to use contraception
- Participants who are unable to safely take study medication, including severe neuropathy, inability to swallow oral medication, malabsorption issues, or known allergy to ATO or ATRA
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: QTX-2101
QTX-2101 (oral arsenic trioxide; ATO) All-trans-retinoic-acid (ATRA; oral) |
The experimental regimen consists of IV ATO administered once daily during induction, given continuously, for up to a maximum of 60 days. During consolidation, QTX-2101 is administered once daily, per investigator's protocol. ATRA is administered orally in two divided daily doses during induction, given continuously until bone marrow remission (not exceeding 60 days). During consolidation, ATRA is taken orally in two divided daily doses following a 2-weeks-on / 2-weeks-off schedule within each 8-week cycle. |
|
Active Comparator: IV ATO
IV Arsenic Trioxide (ATO) All-trans-retinoic-acid (ATRA; oral) |
The comparator regimen consists of IV ATO administered once daily during induction, given continuously, for up to a maximum of 60 days. During consolidation, IV ATO is administered once daily, per investigator's protocol. ATRA is administered orally in two divided daily doses during induction, given continuously until bone marrow remission (not exceeding 60 days). During consolidation, ATRA is taken orally in two divided daily doses following a 2-weeks-on / 2-weeks-off schedule within each 8-week cycle. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum observed plasma (concentration (Cmax) of QTX-2101 for ASIII
Time Frame: Up to 1 cycle of consolidation therapy (each cycle is 8 weeks)
|
Cmax is defined as the maximum observed plasma concentration following administration of [investigational product], determined from plasma concentration-time data. |
Up to 1 cycle of consolidation therapy (each cycle is 8 weeks)
|
|
Molecular complete remission (molecular CR) rate
Time Frame: Up to 60 days of induction and 3 8-week cycles of consolidation treatment
|
mCR is defined as the absence of detectable PML-RARA fusion transcript in bone marrow assessed by a validated quantitative reverse transcription polymerase chain reaction (RT-qPCR) assay .The mCR rate is defined as the proportion of participants achieving molecular remission at the specified assessment time point following induction and consolidation therapy. |
Up to 60 days of induction and 3 8-week cycles of consolidation treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To characterize the event-free survival (EFS) of QTX-2101/ATRA
Time Frame: Assessed for up to 3 years after the first dose of treatment, or until treatment failure (disease progression), death, or study completion, whichever occurs first
|
Assessed for up to 3 years after the first dose of treatment, or until treatment failure (disease progression), death, or study completion, whichever occurs first
|
|
|
To characterize the safety and tolerability of QTX-2101/ATRA and IV ATO/ATRA
Time Frame: Throughout approximately 10 months of study treatment
|
Treatment emergent adverse events |
Throughout approximately 10 months of study treatment
|
|
Area under the plasma concentration-time curve (AUC) of QTX-2101 for ASIII
Time Frame: Up to 10 months
|
AUC is defined as the area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC₀-t) and/or extrapolated to infinity (AUC₀-∞), calculated using noncompartmental methods. |
Up to 10 months
|
|
To complete a model-based concentration QT relationship evaluation
Time Frame: Up to 10 months
|
Time-matched difference in change from baseline in QTcF interval between active treatment and placebo, derived from triplicate 12-lead ECGs at each post-dose time point |
Up to 10 months
|
|
EORTC QLQ-C30 domain unit of measure and measurement tool
Time Frame: Up to 10 months
|
Change from baseline in EORTC QLQ-C30 global health status (0-100 scale) |
Up to 10 months
|
|
EQ-5D-5L domain unit of measure and measurement tool
Time Frame: Up to 10 months
|
Change from baseline in EQ-5D-5L index score (0-100) |
Up to 10 months
|
|
Overall Survival
Time Frame: Assessed for up to 3 years after the first dose of treatment, or until treatment failure (disease progression), death, or study completion, whichever occurs first
|
OS is defined as the time from randomization to death from any cause. Participants who are alive at the time of analysis will be censored at the date last known to be alive. |
Assessed for up to 3 years after the first dose of treatment, or until treatment failure (disease progression), death, or study completion, whichever occurs first
|
|
Event Free Survival (EFS)
Time Frame: Assessed for up to 3 years after the first dose of treatment, or until treatment failure (disease progression), death, or study completion, whichever occurs first
|
EFS is defined as the time from randomization to the first occurrence of any of the following events: failure to achieve hematologic or molecular remission, relapse (hematologic or molecular), or death from any cause. Participants without an event at the time of analysis will be censored at the date of last adequate disease assessment. |
Assessed for up to 3 years after the first dose of treatment, or until treatment failure (disease progression), death, or study completion, whichever occurs first
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms by Histologic Type
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Hemic and Lymphatic Diseases
- Neoplasms
- Leukemia
- Hematologic Neoplasms
- Hematologic Diseases
- Leukemia, Promyelocytic, Acute
- Organic Chemicals
- Retinoids
- Carotenoids
- Polyenes
- Alkenes
- Hydrocarbons, Acyclic
- Hydrocarbons
- Cyclohexenes
- Cyclohexanes
- Cycloparaffins
- Hydrocarbons, Alicyclic
- Hydrocarbons, Cyclic
- Terpenes
- Pigments, Biological
- Biological Factors
- Inorganic Chemicals
- Diterpenes
- Oxides
- Oxygen Compounds
- Vitamin A
- Arsenicals
- Arsenic Trioxide
- Tretinoin
Other Study ID Numbers
- QTX-2101-301
- 2025-524810-28-00 (Ctis)
- 2025 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.